Mitigating impact of SARS-CoV-2 pandemic on available supply for commercialization and programmatic doses required of non-COVID-19 vaccines

In the context of the COVID-19 pandemic and the unprecedented efforts to develop, manufacture, and deliver large quantities of COVID-19 vaccines, the global programmatic doses requirement (PDR) for non-COVID-19 vaccines has been impacted. In parallel risks have emerged for the global supply for these vaccines.

In 2021, the World Health Organization (WHO), as part of the Market Information for Access (MI4A) project, has sought to assess the potential risks and impacts of the SARS-CoV-2 pandemic and COVID-19 vaccine manufacturing and implementation on PDR and vaccine production.

The analysis was conducted leveraging information collected consultations with WHO Regional and Country Offices, partners, several experts and vaccine manufacturers as well as the convening of separate workshops to explore the potential impact and risks and discuss mitigating actions. The public summary of the analysis will be published by end of year on the MI4A website.